These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 16517982)
1. Severe hemolysis following administration of Rh(o)(D) immune globulin in an ITP patient associated with anti-C. Schwartz J; Spitalnik S; Grima KM Blood; 2006 Mar; 107(6):2585. PubMed ID: 16517982 [No Abstract] [Full Text] [Related]
2. A closer look at intravascular hemolysis (IVH) following intravenous anti-D for immune thrombocytopenic purpura (ITP). Tarantino MD; Bussel JB; Cines DB; McCrae KR; Gernsheimer T; Liebman HA; Wong WY; Kulkarni R; Grabowski E; McMillan R Blood; 2007 Jun; 109(12):5527; author reply 5528. PubMed ID: 17554071 [No Abstract] [Full Text] [Related]
3. Delayed hemolysis after intravenous anti-D immune globulin infusion in a patient with idiopathic thrombocytopenic purpura. Rubinstein PG; Chen YH Am J Hematol; 2008 Aug; 83(8):684-5. PubMed ID: 18508323 [No Abstract] [Full Text] [Related]
11. Sequelae of treatment of ITP with anti-D (Rho) immunoglobulin. Imbach P; Kühne T Lancet; 2000 Aug; 356(9228):447-8. PubMed ID: 10981885 [No Abstract] [Full Text] [Related]
12. Renal failure after anti-D globulin treatment of idiopathic thrombocytopenic purpura. Kees-Folts D; Abt AB; Domen RE; Freiberg AS Pediatr Nephrol; 2002 Feb; 17(2):91-6. PubMed ID: 11875670 [TBL] [Abstract][Full Text] [Related]
13. Acute renal failure with hemolysis in a D-mismatched transfusion recipient treated with RhIG. Karp JK; Ness PM Transfusion; 2009 Jun; 49(6):1269; author reply 1269-70. PubMed ID: 19638156 [No Abstract] [Full Text] [Related]
14. What is the mechanism for acute hemolysis occurring in some patients after intravenous anti-D therapy for immune thrombocytopenic purpura? Garratty G Transfusion; 2009 Jun; 49(6):1026-31. PubMed ID: 19638151 [No Abstract] [Full Text] [Related]
16. Evaluation of the effects of and earliest response rate to anti-D treatment in children with chronic idiopathic thrombocytopenic purpura: a pilot study. Yetgin S; Aytaç S; Olcay L; Tunç B; Ozbek N; Aydinok Y Turk J Pediatr; 2010; 52(2):126-31. PubMed ID: 20560246 [TBL] [Abstract][Full Text] [Related]
17. Efficacy, safety, and dose response of intravenous anti-D immune globulin (WinRho SDF) for the treatment of idiopathic thrombocytopenic purpura in children. Freiberg A; Mauger D Semin Hematol; 1998 Jan; 35(1 Suppl 1):23-7. PubMed ID: 9523746 [TBL] [Abstract][Full Text] [Related]
18. Comparison of intravenous immune globulin and high dose anti-D immune globulin as initial therapy for childhood immune thrombocytopenic purpura. Kane I; Ragucci D; Shatat IF; Bussel J; Kalpatthi R Br J Haematol; 2010 Apr; 149(1):79-83. PubMed ID: 20096011 [TBL] [Abstract][Full Text] [Related]
19. Randomized trial of anti-D immunoglobulin versus low-dose intravenous immunoglobulin in the treatment of childhood chronic idiopathic thrombocytopenic purpura. El Alfy MS; Mokhtar GM; El-Laboudy MA; Khalifa AS Acta Haematol; 2006; 115(1-2):46-52. PubMed ID: 16424649 [TBL] [Abstract][Full Text] [Related]